GLP-1 obesity drug sales value rose 72% in September 2026 while units fell 10%
New generics and steady prices drove the jump in value despite fewer units sold, with Eli Lilly's tirzepatide featured in the breakdown.
Recap by typeshit. Post by Facebook on Facebook.